OptimizeRx Corporation is a digital health company providing communications solutions for life sciences companies, physicians, and patients. The company is headquartered in Rochester, Michigan.
| Revenue (TTM) | $107.34M |
| Gross Profit (TTM) | $75.18M |
| EBITDA | $18.86M |
| Operating Margin | 2.00% |
| Return on Equity | 5.56% |
| Return on Assets | 5.43% |
| Revenue/Share (TTM) | $5.76 |
| Book Value | $6.84 |
| Price-to-Book | 0.90 |
| Price-to-Sales (TTM) | 1.07 |
| EV/Revenue | 1.116 |
| EV/EBITDA | 6.30 |
| Quarterly Earnings Growth (YoY) | -66.80% |
| Quarterly Revenue Growth (YoY) | -9.50% |
| Shares Outstanding | $18.77M |
| Float | $14.43M |
| % Insiders | 12.88% |
| % Institutions | 77.92% |
Volatility is currently contracting
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
OptimizeRx Corporation OPRX trimmed its 2026 revenue outlook, reflecting ongoing near-term pressures. Revenues are now expected to be between $95 million and $100 million, compared with the previous range of $109-$114 million.
OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences customers and shorter contract commitments tied in part to most-favored-nation pricing dynamics and other macroeconomic pressures.
– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended March 31, 2026.
